Business Wire

Institute for Rational Drug Policies and European Pirate Party Call on European Commission to Implement Harm Reduction Policies to Help European Citizens Make Positive Lifestyle Choices

Share

A webinar on Citizen Focused Disease Prevention, organised by the Institute for Rational Drug Policies (IRAP) in cooperation with the European Pirates, established that harm reduction policies should be used to help people with a wide range of addictions, including smoking.

“We support the concept of harm reduction. Pirates emphasise the need to focus long-term attention on drug use and addictions,” said Mikuláš Peksa, Czech Green MEP. “We are working on a long-term prevention programme of minimising risks at the national level and at the European level. We must also consider how to minimise the negative impact of government drug policies and laws, and this point of view should also be followed by the European Commission.”

The European Commission currently fails to recognise the potential of harm reduction policies even though there is clear public support for them as shown by the recent Town Hall organised by the Commission on Europe's Beating Cancer Plan. Despite harm reduction being perceived by the Town Hall audience as being extremely important, the Commission still refuses to take harm reduction seriously.

According to Jindrich Voboril, Head of IRAP and former long-term National Anti-Drug Coordinator in the Czech Republic: “We have to consider harm reduction not only as a type of social or health service but as a complex approach that should also be incorporated into law and drug policies.”

Advising how to embrace harm reduction into practice: “One part of it is changing the European Commission’s structure. How can we be effective when illicit drugs are solved with one set of criteria, licit drugs with another and problem gambling is left aside altogether? The current situation does not allow effective solution to drug policies and it is hardly cost-effective. The structure of the Directorate General must be changed and the mandate of the EMCDDA (European Monitoring Centre for Drugs and Drug Addictions) must be strengthened. In the context of the ongoing debate on Europe’s Beating Cancer Plan, it’s time that the European Commission begins to take the concept of harm reduction seriously,” concluded Voboril.

“Harm reduction is a broad concept that can complement other approaches, for example when tackling addiction,” said Kasia Kowalczyk from The Global Public Health Network alongside her colleague David Mackintosh. “Harm Reduction has untapped potential across different areas of public health. It works best through a collaborative approach and engages the beneficiaries of public health services or other interventions.”

During the discussion, Hana Horka from the European Commission’s DG SANTE was not enthusiastic about harmonising approaches to addiction. Ms. Horka, despite endorsing harm reduction policies for drug addiction, did not endorse harm reduction policies for tobacco or alcohol, instead advocating for tax increases and prohibitive measures on tobacco products.

Abstinence should not be regarded as the only option for addicts. The goal of harm reduction policies is to keep people alive, help them to make positive changes in their lives and offer them alternatives that cause less harm.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Queries
Jindřich Vobořil, Head of IRAP
media@jindrichvoboril.cz

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye